Omega Fund Management, LLC 13F holdings
Omega Fund Management, LLC reported 10 positions with a total reported value of $185.7M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: BCAX Bicara Therapeutics Inc. (29.1%), NUVB Nuvation Bio Inc. (24.7%), KMTS Kestra Med Technologies Ltd (14.0%), BBOT BridgeBio Oncology Therapeutics Inc. (13.5%), BBNX Beta Bionics Inc. (11.1%). Against 2026-03-31 it opened 1 new position and exited 1. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Omega Fund Management, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
10 largest of 10 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| BCAX Bicara Therapeutics Inc. | 1,822,150 | $54.1M | 29.1% |
| NUVB Nuvation Bio Inc. | 8,081,089 | $45.9M | 24.7% |
| KMTS Kestra Med Technologies Ltd | 1,022,149 | $26.0M | 14.0% |
| BBOT BridgeBio Oncology Therapeutics Inc. | 3,289,661 | $25.1M | 13.5% |
| BBNX Beta Bionics Inc. | 1,316,183 | $20.6M | 11.1% |
| ALMS Alumis Inc. | 241,255 | $6.8M | 3.7% |
| SANA Sana Biotechnology, Inc. | 843,750 | $2.9M | 1.6% |
| IMA ImageneBio, Inc. | 455,361 | $2.7M | 1.4% |
| ENGN enGene Holdings Inc. | 876,357 | $1.5M | 0.8% |
| ODTX Odyssey Therapeutics Inc. | 2,893 | $54.1K | <0.1% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 1 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ODTX Odyssey Therapeutics Inc. | 2,893 | $54.1K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 1 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| REPL Replimune Group | 248,672 | $1.9M | 1.2% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
No position was increased.
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| BCAX Bicara Therapeutics Inc. | 2,392,150 | 1,822,150 | -23.8% | $54.1M |
CIK 1637359 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
